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CLINICAL INVESTIGATION
Glomerular tissue factor stimulates thromboxane synthesis in
human platelets via thrombin generation
RAYMOND ARDAILLOU, MARCELLE BENS, and THOMAS S. EDGINGTON
INSERM U.64, Tenon Hospital, Paris, France and Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California,
USA
Glomerular tissue factor stimulates thromboxane synthesis in human
platelets via thrombin generation. We have investigated whether or not
tissue factor (TF) which is present in the supernatant of isolated
glomeruli, is responsible for the stimulatory activity of TXB2 produc-
tion by isolated human platelets. Reconstituted TF stimulated TXB2
synthesis in platelets in a dose-dependent manner. This effect was
potentiated in the presence of a mixture of the major fatty acids found
in glomerular supernatants. Addition of a neutralizing anti-TF mono-
clonal antibody abolished both the procoagulant activity and the
platelet-TXB2 stimulatory activity of reconstituted TF and of glomeru-
lar supernatants. Anti-factor Vil/Vila (F Vil/Vila) Fab inhibited in a
dose-dependent manner the platelet-TXB2 stimulatory activity of an
identical dilution of reconstituted TF and of glomerular supernatants,
providing evidence that the functional complex TF.VIIa and not TF
itself was the active agent. Pretreatment of platelets, TF or glomerular
supernatant by hirudin, an inhibitor of thrombin, as well as by anti-
thrombin III heparin, which inhibits both activated factor X and
thrombin also markedly inhibited the synthesis of TXB2 by platelets in
the presence of either TF or glomerular supernatant. Taken together,
these results demonstrate that the stimulatory activity for TXB2 pro-
duction by platelets which is released by the glomerular cells is
attributable to TF. TF does not act directly. Its effect is mediated by
thrombin which is formed de nova at the platelet surface in the presence
of even traces of the plasma coagulation proteins associated with
platelets. TXB2 formation in platelets correlates well with TF concen-
tration in the glomerular supernatant, The possibility of a similar set of
mechanisms associated with glomerular injury may require consider-
ation.
Molecular communication between the capillary wall and
platelets is a topic of wide interest. Endothelial cells are
normally thought to inhibit platelet adhesion and aggregation by
releasing prostacyclin (PGI2) and nitric oxide (NO) which act
synergistically [1, 2]. Injury of the capillary wall leads to
contact between platelets and subendothelial matrix, including
both adhesive proteins and collagen invoking platelet aggrega-
tion. This process is associated with the release from platelets
of adenosine diphosphate (ADP), 5-hydroxytryptamine (5-HT),
platelet activating factor (PAF) and thromboxane A2 (TXA2).
Most of these molecules amplify platelet aggregation and induce
vasoconstriction [3]. Endothelial cells limit these two events by
releasing PGI2 and NO in response to ADP and 5-HT following
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their binding to specific purinergic and serotoninergic receptors
[4]. Injury of the capillary wall may also result in the release of
cell surface membrane vesicles containing tissue factor (TF), a
transmembrane cell surface receptor and cofactor for plasma
factors VII and Vila (F VII and Vila) in the presence of Ca2
[5, 61. The binary complex TF.VIIa is catalytically active and
catalyzes peptide bond cleavages in two plasma proteins, factor
IX (F IX) and factor X (F X). The resultant serine proteases, F
IXa and F Xa, can then proteolytically activate F VII to F VIla
which, associated with TF, forms more catalytic complex
launching the cascade of reactions known as the extrinsic
pathway of coagulation [7].
The above events may occur in all capillary beds. Under-
standing the mechanism of local vasoconstriction and thrombo-
sis in the glomerular capillary tuft is of particular interest since
both play a major role in the development of glomerular
diseases. We previously demonstrated that isolated human
glomeruli release factors which stimulate TXA2 synthesis by
platelets [8]. This stimulation was due in part to the presence in
the medium of saturated and monounsaturated fatty acids
released by the glomeruli, but also to another compound which
was lost during the purification process. We hypothesized it
was a lipoprotein. We and others have also shown that the
medium from incubation of isolated glomeruli contained TF
activity [8, 9]. TF must be inserted in a phospholipid bilayer for
full activity since it is a transmembrane receptor [10, 11] and
preferentially activates F X associated with charged phospho-
lipids [10]. Thus TF could be the unknown product released by
glomeruli which, in addition to fatty acids, stimulates TXA2 in
platelets. The present report provides data to support this
hypothesis. It also shows that neither TF itself nor its complex
with F VII or F VIIa acts directly on platelets. Stimulation of
TXA2 synthesis in platelets depends on the de novo formation
of thrombin at the platelet surface as the final stage of the
coagulation protease cascade initiated by the release of TF from
glomeruli.
Methods
Coagulation proteins and their antibodies
Human brain TF was purified as described [11, 12] and
reconstituted in rabbit brain-derived mixed phospholipid vesi-
des. This preparation used at 1 g/ml in 0.14 M NaCI supple-
mented with 0.5 mg/mI bovine serum albumin (BSA) provided
maximum procoagulant activity (PCA). Munne monoclonal
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antibodies to human TF have been previously described in
detail [13]. We used a neutralizing cocktail of these anti-TF
antibodies. Five g/ml of this preparation inhibited coagulation
of human plasma induced by purified human brain TF. Fab
fragments were prepared from monoclonal antibody TF9-6B4
and were also used at a final working concentration of 5 g/ml.
Fab fragments from a monoclonal antibody against human F
Vu/F Vila that had been purified from plasma were also used to
neutralize F Vu/F Vila activity. A murine monoclonal antibody
was taken as control for anti-TF antibody and anti-TF Fab.
Other materials
They were purchased from the following suppliers: [3H]TXB2
(100 Ci/mmol) from the Radiochemical Centre (Amersham,
UK); fatty acids (myristic, paimitic, stearic, oleic) from Sigma
Chemicals Co. (St. Louis, Missouri, USA); anti-TXB2 antibody
from Institut Pasteur (Paris, France); rat brain thromboplastin
from Stago (Asniêres, France); hirudin from Calbiochem (San
Diego, California, USA); human antithrombin III from Kabi
(Stockholm, Sweden); heparin from Leo (Montigny, France).
Cell preparations
Fresh human platelets were obtained from volunteer venous
blood. Platelet-rich plasma was prepared by centrifugation at
100 g for 10 minutes. It was then mixed with buffer A (10 mM
Tris-HC1 buffer, pH 7.5, containing 135 mrvi NaCI, 10 mM KCI,
10 mM NaCH3COO, 5 mi glucose) supplemented with 1 mivi
EDTA, and was centrifuged at 1,800 g for 10 minutes. After one
washing, the final pellet was resuspended in buffer A. Platelet
suspension contained 60 to 70 x 106 cells/mI. Contamination by
red blood cells and leukocytes was lower than 1% for each.
Human glomeruli were isolated as previously described from
cadaver kidneys judged to be unsuitable for transplantation
[14]. Pooled results are shown for five different human kidneys
which each provided several glomerular preparations. The
pellet of isolated glomeruli containing 0.5 to 1.5 mg protein was
resuspended in 500 d buffer A and incubated at 37°C for 10
minutes. The glomerular suspension was then spun at 1,000 g
for 10 minutes and the cell-free supernatant hereafter called
glomerular supernatant (S) was used within three hours. In
some experiments, S was submitted to heat denaturation (100°C
for 30 minutes) before study. The protein contents of platelets
and glomerular suspensions were determined by the method of
Lowry et a! [15].
Procoagulant activity (PCA) study
The recalcification time of normal platelet-poor plasma (PPP)
was assessed as described by De Prost and Kanfer [91. In brief,
100 d of S or 100 j.d of dilute preparation of reconstituted TF
were mixed with 100 d of PPP. One hundred d of 30mM CaCl2
were then added and the clotting time was recorded. Clotting
times were compared with a standard curve generated using rat
brain thromboplastin. This standard preparation was taken
arbitrarily to contain 1,000 TF U/mi. The PCA of serial dilutions
of reconstituted purified human TF (1:2 to 1:10,000) was mea-
sured. Dilution 1:64 (approximately 8 ng/ml of effective vesicle
surface exposed TF) corresponded to a PCA of 6 U/mI.
Platelet TXB2 stimulatory activity assay
One hundred jsl of S (100 to 300 sg protein) were added to 100
d of platelet suspension (50 to 100 sg protein) in buffer A. One
hundred d of control platelet suspension were incubated in
parallel with 100 d buffer alone. Incubation was performed at
37°C for 10 minutes in the presence of 2 m'vi CaCI2. The reaction
was stopped by rapidly cooling at 0°C followed by centrifuga-
tion at 1,800 g for 10 minutes. The supernatants were collected
and kept at —20°C before TXB2 assay. The platelet TXB2
stimulatory activity of reconstituted TF was also measured
unoer similar conditions. Final dilutions of 1:32 or 1:64 (12 to 6
U/mi) were studied, unless stated otherwise, because they
corresponded to the PCA usually found in S. Radioimmunoas-
say of TXB2 was performed as described by Sors et al [16].
Cross reactivity between anti-TXB2 antibody and other pros-
taglandins (PG) was less than 0.1%. Fifty percent inhibition of
binding was achieved with 18.5 pg TXB2. Results were the
means of three values obtained at different dilutions.
Effect of antibodies against TF and F VII, coagulation
inhibitors and fatty acids
To test the effect of anti-TF antibodies or anti-TF Fab, 100 l
of S or of dilute preparation of reconstituted TF were preincu-
bated with 100 l of anti-TF antibody, 100 d of nonspecific IgG
solution or 100 p1 of buffer for 20 minutes at room temperature.
The final concentration of antibody was 5 g/ml. After prein-
cubation, the sample was equally divided into two 100 p1
aliquots for measuring PCA and platelet TXB2 stimulatory
activity, respectively. For the latter assay, 100 p1 of platelet
suspension in buffer A were added. The control preparation
consisted of 100 p1 of buffer plus 100 pi of platelet suspension.
To test the effect of neutralizing anti-F Vil/Vila Fab, 100 1d of
platelet suspension were preincubated with 10 p1 of anti-F
VII! Vila Fab or 10 p1 of nonspecific IgG solution for 20 minutes
at room temperature. The final concentration of anti-F VII Fab
varied from 0.001 to 50 g!m1. Then 100 p1 of S, 100 1d of dilute
preparation of reconstituted TF or 100 p1 of buffer were added
to the pretreated platelets. Incubation was continued for 10
minutes at 37°C after addition of 2 mrvi CaC12 and platelet TXB2
production was measured as stated above.
We also studied the consequence of the interruption of the
coagulation protease cascade at later steps than the formation
of the complex TF.F Vil/VIla. Either the platelets or the two
platelet TXB2 stimulating agents studied (S and reconstituted
TF) were preincubated for 20 minutes at room temperature with
hirudin (5 U/mI), a potent and specific thrombin inhibitor, or the
mixture antithrombin IlI-heparin (1 U/mI for each) which inhib-
its both thrombin and factor Xa. Then, treated platelets were
incubated with untreated agents or vice-versa for 10 minutes at
37°C in the presence of 2 mrvi CaCI2. Control TXB2 production
was also measured after incubation of untreated platelets with
untreated agents.
The effect of exogenous fatty acids in combination with TF
was evaluated. Concentrated methanol solutions of different
fatty acids (50, 40 and 20 m for myristic, oleic and stearic
acids, respectively) were stored at 4°C. Palmitic acid was stored
at 40 m in 1-propanolol, These four fatty acids were studied as
a mixture containing the same concentrations as previously
described [81 which had been chosen in relation with their mean
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Fig. 1. Thromboxane '2 (TXB2) production by human platelets plotted
against increasing dilutions of tissue factor (TF) with (U) or without (0)
addition of a mixture of saturated and monounsaturated fatty acids
(Methods). The effect of the fatty acid mixture alone is shown in the
inset. Means se of results are shown for 7 experiments. Data were
analyzed using analysis of variance. The effects of TF and of the fatty
acid mixture are significant (P < 0.01) and interact significantly (P <
0.01).
levels in S and their solubility (125 jsM myristic acid, 100 LM
palmitic acid, 100 sM stearic acid and 10 sM oleic acid). One
hundred s1 of platelet suspension were incubated in buffer A
containing 2 mrvi CaCI2 for 10 minutes at 37°C in the presence of
dilute TF with and without addition of the fatty acid mixture.
Statistical analysis
Results are expressed as means standard error of the mean
(sEM). Comparisons between means were performed using the
non parametric test of Wilcoxon for paired data or analysis of
variance as appropriate. Relationship between two parameters
was studied by regression analysis.
Results
Effect of TF on TXB2 production in human platelets
Undiluted TF (1 g/ml) stimulated a more than 200-fold
increase of TXB2 synthesis in platelets (79.3 26.6 vs. 0.35
0.03 nglml). The degree of stimulation progressively decreased
at decreasing concentrations of TF but was still marked (6,4
3.1 ng/ml) at the highest dilution studied of 1:256. The relation-
ship between TXB2 production and TF concentration was
non-linear (Fig. 1). As previously reported [8], the mixture of
exogenous fatty acids that are the most abundant in S also
stimulated TXB2 production in platelets by about eightfold (2.07
0.41 vs. 0.35 0.03 ng/ml). At all dilutions of TF the fatty
acid mixture potentiated the effect of TF as shown by the
significant interaction (P <0.01) between both treatments.
To determine whether it was possible to mimic the stimula-
Table 1. Comparison between the stimulatory effects of glomerular
supernatants and tissue factor plus fatty acids at concentrations close
to those found in glomerular supernatants on TXB2 synthesis
in platelets
Glomerular Tissue factor
Experiment supernatant plus fatty acids
4.9 13.5
2 2.7 2.3
3 4.9 8.1
4 75.0 52.5
5 4.0 1.7
6 60.0 34.0
7 21.7 52.7
Mean SE 24.7 11.4 23.5 8.5
TXB2 production is expressed as ng/ml. Tissue factor was used at a
dilution of 1:32 (12 U/lOO jsl) or 1:64(6 Ut 100 pd). The mixture of fatty
acids included myristic acid, stearic acid, palmitic acid (100 M each)
and oleic acid (10 /.LM).
tory effect of different S on platelet TXB2 synthesis by adding
fatty acids to solutions of TF, the dilutions were chosen to give
the same PCA as the S tested. Table 1 shows the results
obtained with seven different samples of S and the correspond-
ing "reconstituted" preparations. No significant difference was
observed between the platelet TXB2 stimulatory activities of
experimental S and "reconstituted" S. Moreover, there was a
significant correlation between both parameters (r = 0.77; P <
0.05).
Effect of anti-TF antibody on platelet TXB2 stimulatory
activity and PCA of S and reconstituted TF
Production of TXB2 by human platelets was markedly stim-
ulated relative to the basal level in the presence of S (12.4 4.2
vs. 0.9 0.3 ng/ml; Fig. 2). Addition of nonspecific IgG to S did
not modify this stimulatory effect (11.0 4.0 ng/ml). In con-
trast, preincubation of S with either anti-TF monoclonal anti-
bodies or anti-TF Fab prevented S-dependent stimulation.
Total suppression (1.1 0.4 ng/ml) was obtained with anti-TF
antibody and almost total suppression (2.0 1.1 nglml) with
anti-TF Fab. Similar results were obtained for PCA of S.
Preincubation of S with nonspecific monoclonal IgG had no
effect (5.9 1.1 and 6.1 1.1 U/mI for treated and untreated
samples, respectively). In contrast, preincubation of S with
either anti-TF antibody or anti-TF Fab significantly prevented S
stimulation of PCA (0.38 0.14 and 0.47 0.08 U/mI,
respectively).
Parallel experiments were performed with reconstituted TF
at dilutions corresponding to those found in S (Fig. 3). Pretreat-
ment of TF by nonspecific IgG changed neither the platelet-
TXB2 stimulatory effect nor the PCA stimulation obtained with
TF alone. In contrast, pretreatment of TF by anti-TF antibody
markedly inhibited these two effects. Anti-TF Fab pretreatment
also significantly inhibited PCA, but not TXB2 production in
platelets because of large dispersion of the individual values for
untreated and treated samples.
Effects of anti-F VII Fab on platelet-TXB2 stimulatoty
activity of S and reconstituted TF
Pretreatment of platelets by anti-F VIl/Vila Fab did not
modify basal TXB2 production. In contrast, it inhibited the
TXB2 stimulatory effect of S and TF. Figure 4 shows the results
100
50
1 1/2 1/4 1/8 1/16 1/32 1/64 1/128 1/256
TF
Fig. 2. Stimulatory activity of glomerular
supernatants (S) on thromboxane B2 (TXB2)
production in human platelets (A) and
procoagulant activity (PCA) of the same S (B)
under control conditions (El) and after
treatment of S by nonspecific IgG (a), anti-
tissue factor (TF) antibody (U), or anti-TF
Fab (D). Mean basal TXB2 production by
platelets 2 SE is shown. Means SE are
given for 17 experiments except for the anti-
TF Fab studies (7 experiments). Results were
analyzed using the rank test of Wilcoxon for
paired data. For TXB2 production, the effects
of S + nonspecific IgG versus S are not
significantly different, whereas those of S +
anti-TF ab and S + anti-TF Fab versus S are
significantly different (P < 0.01 and P < 0.05,
respectively). The effect of S on basal TXB2
production is significant (P < 0.01). For PCA,
the effects of S + nonspecific IgG versus S
are not significantly different whereas those of
S + anti-TFab and S + anti-TF Fab versus S
are significantly different (P < 0.01 and P <
0.05, respectively).
Fig. 3. Stimulatory activity of reconstituted
tissue factor (TF) on thromboxane B2 (TXB2)
production in human platelets (A) and
procoagulant activity (PCA) of the same
preparations of TF (B) under control
conditions (El) and after treatment of TF by
nonspecific IgG (a), anti-TF antibody (U) or
anti-TF Fab (Q). Mean basal TXB2
production by platelets 2 SE 15 shown.
Means SE are given for 8 experiments.
Results were analyzed using the rank test of
Wilcoxon for paired data. For TXB2
production, the effects of TF ÷ nonspecific
IgG and TF + anti-TF Fab versus TF are not
significantly different whereas those of TF +
anti-TF ab versus TF are significantly
different (P < 0.05). The effect of TF on basal
TXB2 production is significant (P < 0.01). For
PCA, the effects of TF + nonspecific IgG
versus TF are not significantly different,
whereas those of TF -I- anti-TF ab and TF +
anti-TF Fab versus TF are significantly
different (P < 0.05).
of two representative experiments. TXB2 production was high
in the presence of S or TF in the absence of neutralizing anti-F
Vil/Vila Fab (5 and 80 times basal value with S, 22 and 155
times basal value with TF for these two experiments, respec-
tively). Stimulation persisted at the three lowest concentrations
of anti-F Vil/Vila Fab tested (0.001, 0.005 and 0.01 g/ml).
Inhibition of TXB2 stimulation was significant at 0.05 g/ml and
total at and above 0.1 jg!ml. Figure 5 shows the results
obtained at high concentrations of anti-F Vil/Vila Fab. The
results confirm the stimulation of TXB2 production in human
platelets in the presence of S or TF when the platelets were not
treated by anti-F Vil/Vila Fab. Basal production of TXB2 by
platelets was not modified by anti-F Vil/Vila Fab even at the
highest concentration studied (50 ig/ml). In contrast, TF- and
S-dependent TXB2 production were not different from basal
values after pretreatment of platelets by concentrations of
anti-F Vil/Vila Fab equal to or higher than 5 sg/ml.
Effects of hirudin and of the mixture antithrombin IJI-heparin
on platelet-TXB2 stimulatory activity and PCA of S and
reconstituted TF
Addition of hirudin to platelets did not modify basal TXB2
production whereas it markedly inhibited 5- or TF-dependent
TXB2 production. Both agents were still stimulatory in a
significant manner (P < 0.05), but the factor of stimulation was
low (x 1.4 and x 1.3 for S and TF, respectively) contrasting
with that obtained under control conditions (x 55 and X 57 for
S and TF, respectively). Similarly, addition of hirudin to S or
TF blocked the stimulation of TXB2 synthesis. Only, the effect
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Anti-FVII Fab, sg/mI
Fig. 5. TXB2 production by human platelets
plotted against anti-F VIII Vila Fab at high
concentrations under control conditions (A),
in the presence of glomerular supernatant (B)
_________________
or tissue factor (C). The results of two
20 50 experiments (open and closed circles,
respectively) are shown. Note the different
scales on the ordinate axis.
Table 2. Effect of pretreatment by hirudin of platelets or agents (glomerular supematant or tissue factor) on TXB2 synthesis in platelets
Control Pretreatment of platelets Pretreatment of agents
Experiment Buffer
Glomerular
supernatant
Tissue
factor Buffer
Glomerular Tissue
supernatant factor Buffer
Glomerular
supernatant
Tissue
factor
1
2
3
4
5
6
Mean se
2.06
2.55
2.15
3.08
2.90
2.10
2.47
5.68
550.0
6.20
130.0
10.75
112.50
135.8a
15.12
512.5
105.0
62.0
44.5
107.5
141.la
2.4
2.43
2.85
3.90
3.60
1.88
2.84
5.03 3.23
3.35 4.25
5.15 2.85
4.55 4.45
4.35 3.90
2.25 3.35
4.IP 3.67°
2.11
2.10
1.88
2.45
3.10
1.34
2.16
4.83
3.03
4.05
4.03
3.70
1.73
3.56a
2.88
2.35
1.78
3.00
2.90
2.50
2.57
TXB2 is expressed as ng/ml, Effect of glomerular supernatant or of tissue factor was compared with that of buffer under the three conditions
studied (control, pretreatment of platelets, pretreatment of agents) using Wilcoxon test for paired data.a < 0.05
Ill-heparin; P < 0.05) and of TF (2.24 1.44 U/mi with hirudin
and 1.5 1.2 U/mI with antithrombin IlI-heparin; P < 0.05 and
0.01, respectively).
Effect of heat denaturation on platelet-TXB2 stimulatory
activity and PCA of S and reconstituted TF
Brief heat denaturation did not significantly modify the plate-
let-TXB2 stimulatory activity of S. The mean value was lower
with than without 100°C treatment, but the level of significance
(P < 0.05) was not reached due to the dispersion of the data.
Moreover, TXB2 production by platelets in the presence of
heat-denaturated specimens was markedly higher than under
basal condition (P < 0.01), confirming the persistence of a
stimulatory activity. PCA was significantly diminished (P <
0.05) with boiled samples, but the degree of inhibition was
relatively small (20%; Table 4).
Discussion
The present data demonstrate that TF released by human
glomeruli strongly stimulates TXB2 synthesis in platelets. Renal
glomeruli are sites of prominent TF expression. Using immu-
nohistochemistry techniques, Drake, Morrissey and Edgington
[17] examined sections of human kidneys and reported that
glomerular epithelial and mesangial cells reacted strongly to
specific anti-TF monoclonal antibodies whereas glomerular
capillary endothelium did not. Parietal epithelial cells of the
Bowman's capsule were reactive. TF production by cultured
rat mesangial cells has also been demonstrated [18]. These
results are in agreement with the presence of PCA in the
incubation medium of human isolated glomeruli [8, 9]. TF
synthesis and release may be modulated by several factors
including cytokines and immune complexes [18—20]. These two
types of mediators play a key role in the development of
glomerulonephritis. Therefore it seems logical to hypothesize
that TF may be produced in excess and become involved, in
addition to other autacoids, in glomerular injury.
The only biological effect of TF described to date is its
receptor cofactor function for F Vila and its augmentation of
activation of F VII to F Vila by Xa when F VII is bound. The
functional complex TF.F Vila initiates the coagulation process
40
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Table 3. Effect of pretreatment by antithrombin Ill-heparin of platelets or agents (glomerular supernatant or tissue factor) on TXB2 synthesis
in platelets
Control Pretreatment of platelets Pretreatment of agents
Glomerular Tissue Glomerular TissueGlomerular Tissue
Experiment Buffer supernatant factor Buffer supernatant factor Buffer supernatant factor
1 0.95 62.5 127.5 0.76 1.08 0.95 0.44 1.03 0.62
2 2.1 112.5 107.5 1.60 1.36 2.33 0.92 1.15 1.59
3 1.78 2.50 100.0 1.25 1.44 1.38 0.99 1.39 0.89
4 1.15 7.60 58.0 0.58 0.71 0.61 0.36 0.59 0.44
5 2.18 324.0 334,0 1.28 1.12 1.33 1.38 1.15 1.43
6 1.42 270.0 316.0 0.78 0.51 0.86 1.85 0.70 0.38
Mean SEM 1.59 129.85a 173.83a 1.04 1.04 1.24 0.99 1.00 0.89
TXB, is expressed as ng/ml. Effect of glomerular supernatant or of tissue factor was compared with that of buffer under the three conditions
studied (control, pretreatment of platelets, pretreatment of agents) using Wilcoxon test for paired data.
a p < 0.05
Table 4. Effect of 100°C treatment on platelet-TXB2 stimulatory
activity (ng/mI) and procoagulant activity (U/mi) of
glomerular supernatants
Boiled
Platelet Glomerular glomerular
alone supernatant supernatant
Platelet-TXB2 stimulatory 0.87 0.14 16.5 5.1 10.0 3.0
activity (N = 12)
Procoagulant activity — 5.8 1.4 4.6 1.1(N=7)
Means SE are shown. Control and heat-denaturated samples were
compared using the rank test of Wilcoxon for paired data. No significant
difference was observed for platelet-TXB2 stimulatory activity; P <
0.05 for procoagulant activity.
by converting F IX and F X into F IXa and F Xa, respectively.
This leads to assembly of F Va.Xa, the prothrombinase com-
plex followed by the formation of thrombin from prothrombin in
the presence of the complex F Xa.F Va. All these events
require the presence of plasma coagulation serine protease
zymogens and cofactors which were not provided in our incu-
bation medium. However, extremely small amounts of F Vila
are necessary for the formation of the active binary complex
TF.VIIa which is catalytically much more efficient than free F
VITa in the presence of phospholipids and substrate [10, 21]. It
is likely that traces of F VII or Vila adsorbed to the surface of
platelets were sufficient to allow the formation of this binary
complex with TF added or present in S since preincubation of
the platelet suspension with anti-F Vu/VITa Fab inhibited the
platelet-TXB, stimulation by S and reconstituted TF.
Platelets were also the source of the other precursors neces-
sary to the formation of thrombin, which must have been
present at their surface. It is clear that no preformed thrombin
was provided by the platelets or the gloinerular supernatant
since: (i) anti-TF antibodies or anti-F VII Fab prevented the
stimulatory effect of S; (ii) hirudin did not inhibit basal TXB2
production. Thrombin is likely to have been formed as soon as
reconstituted TF or S which contains TF was incubated with
platelets. The present study thus indicates that TF released by
glomerular cells is the initiator of a cascade of reactions
resulting in thrombin formation at the platelet surface, and that
this process only requires trace amounts of plasma precursors
carried over on the platelets. That TF present in S was
responsible for TXB2 production in platelets via de novo
thrombin formation can be affirmed on the following grounds:
(i) Reconstituted TF stimulated TXB2 production in platelets in
a concentration-depending manner; (ii) PCA of S was in the
range of 6 to 12 U/mi, corresponding to dilutions of reconsti-
tuted TF of 1:64 to 1:32. The stimulation of TXB2 production by
platelets was comparable for S and for TF at these dilutions
after addition of unsaturated fatty acids to mimic the composi-
tion of S; (iii) Anti-TF antibody markedly inhibited both the
PCA and the platelet-TXB2 stimulatory activity of S and
reconstituted TF whereas nonspecific IgG was inactive; (iv)
Anti-F Vu/VITa Fab inhibited the platelet TXB2 stimulation by
S and reconstituted TF, indicating that the initiation of the
process was attributable to the complex TF.F VITa; (v) Heat
denaturation of S maintained most of the PCA and platelet
TXB2 stimulatory activity consistent with the relative thermal
stability of TF; (vi) Pretreatment of platelets, S or reconstituted
TF by hirudin, a thrombin inhibitor, markedly inhibited both
the PCA and platelet-TXB2 stimulatory activity of both S and
reconstituted TF; (vii) Similar results were obtained with the
mixture antithrombin III-hepann which inhibits both F Xa and
thrombin.
The final coagulation protease effector of TF action is throm-
bin. Activation of platelets by thrombin is a receptor-mediated
event [22]. The platelet receptor recognizes that region on the
thrombin molecule that is blocked by hirudin [23], which
explains the inhibitory role of hirudin on the stimulatory effect
of S and TF. Thrombin binding to platelets results in phospho-
lipase C activation, Ca2 mobilization and TXB2 synthesis [24].
This study confirms that unsaturated fatty acids stimulate
TXB2 production in platelets. Moreover, we show that fatty
acids potentiate the stimulatory effect of TF. The biological
effect of TF depends on its insertion into a phospholipid bilayer
and is optimized by charged phospholipids which facilitate
more efficient FX activation [10]. Acidic phospholipids such as
phosphatidylserine increase the apparent affinity of F VII for
TF according to a model of positive cooperativity [6]. Thus it is
likely that addition of fatty acids produced a similar effect. The
maintenance of PCA and platelet-TXB2 stimulatory activity in
boiled samples of S also suggests that the phospholipid envi-
ronment of TF prevented protein denaturation during ebulli-
tion.
TXB2 synthesis occurs in platelets which have been activated
by contact with the wall of a damaged blood vessel or by soluble
agonists including ADP, vasopressin, 5-HT and thrombin.
Because of its role in local thrombosis, reduction of the
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filtration surface and alteration of the capillary wall permeabil-
ity, TXA2, the active precursor of TXB2, is considered as a
major mediator in the development of glomerular injury in acute
glomerulonephritis or experimental chronic renal failure [25].
The fact that TF also stimulates TXA2 synthesis in platelets
shows that the capillary wall produces platelet activation not
only by contact between collagen fibers or subendothelial
matrix and platelets but also by release of TF in the medium or
by contact between platelets and TF expressed at the surface of
the cells. The role of TF should be particularly evident in
glomerulonephritis where local TF production can increase.
Such an increase has been reported in rabbit nephrotoxic
nephritis [26, 27] and in mercuric chloride-induced autoimmune
nephritis [28]. The latter condition is of particular interest
because the source of TF appears to be resident glomerular
cells rather than macrophages which are relatively few in this
model.
Interactions between glomerular autacoids are an important
mechanism of glomerular injury. They represent a mode of cell
cooperation between glomerular resident cells and bone mar-
row-derived cells which amplifies or inhibits the synthesis of
toxic agents and potentiates or decreases their actions [29]. The
present study provides a novel example of interactive process
in which glomerular cells by releasing TF are a messenger
source to target TXA2-producing platelets. TF does not act
directly on platelets. Its effect is mediated by thrombin but it is
noteworthy that TXB2 production was correlated with TF
concentration in the medium. This suggests that TF controls, at
its initial step, the magnitude of the subsequent amplification
system which results in thrombin formation. TXB2 represents
itself the first component of a cascade since TXA2 is a toxic
product which in turn will act on platelets and glomerular cells
in an autocrine and paracrine fashion.
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